文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

成人完成2剂和3剂mRNA疫苗后对COVID-19相关急诊和紧急护理就诊及住院的保护效果衰减——VISION网络10州2021年8月至2022年1月

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-02-18

CDC建议所有≥12岁人群在完成mRNA疫苗基础免疫≥5个月后接种加强针,免疫功能低下者接种第三剂基础针。VISION网络采用检测阴性病例对照设计分析2021年8月26日至2022年1月22日10州241,204次急诊/紧急护理就诊和93,408例住院,发现Delta和Omicron优势期所有评估时间点3剂疫苗保护效果均高于2剂,但随时间衰减;Omicron期3剂后对急诊/紧急护理就诊保护效果从接种后2个月内的87%降至接种4-5个月后的66%,对住院保护效果从91%降至≥4个月后的78%。

要点

  • Omicron优势期3剂后对急诊/紧急护理就诊的保护效果从2个月内的87%降至4-5个月后的66%。
  • Omicron优势期3剂后对住院的保护效果从2个月内的91%降至≥4个月后的78%。
  • Delta和Omicron优势期所有评估时间点3剂保护效果均高于2剂,但均随时间衰减。

核心结论

  • 所有符合条件者应保持按推荐完成COVID-19疫苗接种,以最佳预防COVID-19相关住院和急诊/紧急护理就诊。

研究设计与样本

  • 采用检测阴性病例对照设计,使用VISION网络8个站点数据,分析2021年8月26日至2022年1月22日10州≥18岁成人241,204次急诊/紧急护理就诊和93,408例住院。
  • 3剂组包括完成基础免疫第三剂或2剂基础免疫后加强针(包括减剂量Moderna加强针)者。
  • 分析Delta优势期和Omicron优势期(各变异株占测序分离株≥50%的时期)。

主要发现

  • Delta和Omicron优势期所有评估时间点,接种2剂和3剂后的疫苗保护效果在Omicron优势期均低于Delta优势期。
  • 两个时期接种第三剂后的保护效果均高于第二剂,但保护效果随接种后时间延长而衰减。
  • Omicron优势期,第三剂后对急诊/紧急护理就诊的保护效果在接种后2个月内为87%,在接种4-5个月后降至66%。
  • Omicron优势期,第三剂后对住院的保护效果在接种后2个月内为91%,在接种≥4个月后降至78%。
  • Delta和Omicron优势期,对住院的保护效果总体高于对急诊/紧急护理就诊的保护效果。

临床怎么用

  • CDC建议所有≥12岁人群在完成mRNA疫苗基础免疫≥5个月后接种COVID-19 mRNA疫苗加强针。
  • CDC建议免疫功能低下者接种第三剂基础针。
  • 所有符合条件者应保持按推荐完成COVID-19疫苗接种。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CDC recommends that all persons aged ≥12 years receive a booster dose of COVID-19 mRNA vaccine ≥5 months after completion of a primary mRNA vaccination series and that immunocompromised persons receive a third primary dose.* Waning of vaccine protection after 2 doses of mRNA vaccine has been observed during the period of the SARS-CoV-2 B.1.617.2 (Delta) variant predominance† (1-5), but little is known about durability of protection after 3 doses during periods of Delta or SARS-CoV-2 B.1.1.529 (Omicron) variant predominance. A test-negative case-control study design using data from eight VISION Network sites§ examined vaccine effectiveness (VE) against COVID-19 emergency department/urgent care (ED/UC) visits and hospitalizations among U.S. adults aged ≥18 years at various time points after receipt of a second or third vaccine dose during two periods: Delta variant predominance and Omicron variant predominance (i.e., periods when each variant accounted for ≥50% of sequenced isolates).¶ Persons categorized as having received 3 doses included those who received a third dose in a primary series or a booster dose after a 2 dose primary series (including the reduced-dosage Moderna booster). The VISION Network analyzed 241,204 ED/UC encounters** and 93,408 hospitalizations across 10 states during August 26, 2021-January 22, 2022. VE after receipt of both 2 and 3 doses was lower during the Omicron-predominant than during the Delta-predominant period at all time points evaluated. During both periods, VE after receipt of a third dose was higher than that after a second dose; however, VE waned with increasing time since vaccination. During the Omicron period, VE against ED/UC visits was 87% during the first 2 months after a third dose and decreased to 66% among those vaccinated 4-5 months earlier; VE against hospitalizations was 91% during the first 2 months following a third dose and decreased to 78% ≥4 months after a third dose. For both Delta- and Omicron-predominant periods, VE was generally higher for protection against hospitalizations than against ED/UC visits. All eligible persons should remain up to date with recommended COVID-19 vaccinations to best protect against COVID-19-associated hospitalizations and ED/UC visits.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35176007. doi:10.15585/mmwr.mm7107e2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。